Children Affected by Rare Disease and Their Families Network
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Rare Diseases
- Sponsor
- Silke Wiegand-Grefe, Prof. Dr.
- Enrollment
- 687
- Locations
- 17
- Primary Endpoint
- Mental health of parents (SCID)
- Status
- Active, Not Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Families of children with rare diseases (i.e., not more than 5 out of 10.000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and his/her siblings. The project at hand will test two innovative forms of care (CARE-FAM and WEP-CARE) at 17 sites in 12 federal states of Germany. The goal is to improve the mental health and quality of life of children affected by rare diseases and their relatives in a sustainable manner. If successful, these interventions will be introduced into regular care.
Detailed Description
The central objective of the study at hand is to close the supply gap for families with children and adolescents affected by rare diseases. Two innovative forms of care (CARE-FAM and WEP-CARE) will be implemented and evaluated at the 18 participating study sites. Both interventions include psychological diagnostics, early detection and treatment of concomitant mental diseases. The study is a prospective, randomized controlled multicenter study (RCT) with a factorial design with four groups: CAREFAM (face to face), WEP-CARE (online), both interventions, control group (TAU = treatment as usual). Central psychosocial outcomes will be assessed at four time points (i.e., Baseline and after six, 12 and 18 months) from the perspectives of the parents, the affected child and the siblings (0 - 9 years only external assessment; from 10 years of age additional self-assessment) and the professionals.
Investigators
Silke Wiegand-Grefe, Prof. Dr.
Prof. Dr.
Universitätsklinikum Hamburg-Eppendorf
Eligibility Criteria
Inclusion Criteria
- •Family with at least one child between 0 and 21 years with a rare disease or a suspected rare disease.
- •Consent to participate in the study.
- •Sufficient knowledge of the German language of parents and children.
- •Insured at the participating insurance companies.
Exclusion Criteria
- •Severe psychiatric disorders and impairments with acute symptoms such as suicidal tendencies, severe depression, addictions, acute psychotic symptoms etc., which will not be sufficiently supplied by this new low-frequency intervention. Children and parents with acute treatment demand in the control group will be placed at psychotherapists. Nevertheless, they stay in the control group.
Outcomes
Primary Outcomes
Mental health of parents (SCID)
Time Frame: Change from baseline of the study at 6,12 and 18 months after the randomization
Proportion of parents without mental abnormities among the parents with initial mental abnormities, assessed by the external, independent "Structured clinical interview for DSM-IV" (SCID; Wittchen, Zaudig \& Fydrich,1997) 18 months after.
Secondary Outcomes
- Sociodemographic information of the parents(At baseline of the study)
- Mental health of the chronically-ill children/adolescents and the siblings (Kiddie-SADS-PL)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Coping of the parents (CHIP-D)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Relationships between siblings (SRQ)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Satisfaction with the relationship and parenting relationship of the parents (PFB)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Body-related eating behaviour of the chronically-ill children/adolescents (ChEDE-Q8)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Health-related quality of life of the parents (SF-12)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Health-related quality of life of the chronically-ill children/adolescents (Kidscreen-27)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Health-related quality of life of the parents (EQ-5D)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Health-related quality of life of the chronically-ill children/adolescents (DCGM-37)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Mental health of the parents (BSI)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Health-related quality of life of the parents (ULQIE)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Mental health of the parents (PHQ)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Psychiatric disorders of the chronically-ill children/adolescents and the siblings (CBCL)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Psychiatric disorders of the chronically-ill children/adolescents and the siblings (YSR)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Patient satisfaction (ZUF-8) Patient satisfaction(Change from 6 months after randomization at 12 and 18 months.)
- Coping of the chronically-ill children/adolescents and the siblings (Kidcope)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Family functioning (GARF)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Social support of the parents, of the chronically-ill children/adolescents and of the siblings (OSSQ)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Eating behaviour of the chronically-ill children/adolescents (EDY-Q)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Elimination disorders of the chronically-ill children/adolescents (Anamnesebogen Enuresis/Funktionelle Harninkontinenz)(Change from baseline of the study at 6,12 and 18 months after the randomization)
- Treatment costs of the parents (CSSRI-DE)(Change from baseline of the study at 6 months after the randomization)
- Treatment costs of the chronically-ill children/adolescents and the siblings (CAMHSRI-DE)(Change from baseline of the study at 6 months after the randomization)
- Treatment assessment (FBB-T)(Change from 6 months after randomization at 12 and 18 months.)